文献速递造血干细胞移植与细胞治疗白血病

成人白血病患者接受单份脐血移植联用或不联用第三方供者CD34+细胞的比较

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.
PubMed 文献 · Blood Adv · 2017-06-20

该回顾性研究比较了135例接受单份脐血移植(sUCBT)与72例接受脐血联合第三方供者CD34+细胞共输注(Haplo-Cord)的成人急性白血病患者。多因素分析显示Haplo-Cord组中性粒细胞和血小板恢复更快、慢性GVHD发生率更低,但两组非复发死亡、复发、无病生存和GVHD/无复发生存相似;AML患者中Haplo-Cord组复发率显著更高。

要点

  • Haplo-Cord组中性粒细胞恢复更快(HR 2.3,95%CI 1.5-3.3,P<.001)。
  • Haplo-Cord组血小板恢复更快(HR 1.6,95%CI 1.2-2.3,P=.015)。
  • Haplo-Cord组慢性GVHD发生率更低(相对风险0.5,95%CI 0.3-0.8,P=.01)。

核心结论

  • Haplo-Cord是加速中性粒细胞和血小板恢复的有效策略,在特定治疗平台下sUCBT与Haplo-Cord提供相似的长期结局。

研究设计与样本

  • 回顾性比较研究,纳入西班牙造血干细胞移植协作组不同中心的成人急性白血病患者,sUCBT组135例,Haplo-Cord组72例。

主要发现

  • 多因素分析中,Haplo-Cord组中性粒细胞恢复更快(HR 2.3;95%CI 1.5-3.3;P<.001),血小板恢复更快(HR 1.6;95%CI 1.2-2.3;P=.015),慢性GVHD发生率更低(相对风险0.5;95%CI 0.3-0.8;P=.01)。
  • 两组非复发死亡、复发、无病生存和GVHD/无复发生存相似。
  • 急性髓系白血病和急性淋巴细胞白血病患者的无病生存均无显著差异;但接受Haplo-Cord治疗的急性髓系白血病患者复发率显著更高(HR 2.3;95%CI 1-5.4;P=.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We retrospectively compared the clinical outcomes of adults with acute leukemia who received single-unit umbilical cord blood (UCB) transplantation (sUCBT) (n = 135) or stem cell transplant using coinfusion of a UCB graft with CD34+ cells from a third-party donor (Haplo-Cord) (n = 72) at different institutions within the Grupo Español de Trasplante Hematopoyético. In multivariable analysis, patients in the Haplo-Cord group showed more rapid neutrophil (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.5-3.3; P < .001) and platelet recovery (HR, 1.6; 95% CI, 1.2-2.3; P = .015) and lower incidence of chronic graft-versus-host disease (GVHD) (relative risk, 0.5; 95% CI, 0.3-0.8; P = .01). Nonrelapse mortality, relapse, disease-free survival (DFS), and GVHD/relapse-free survival were similar in the 2 groups. Regarding disease-specific outcomes, DFS in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia patients was not significantly different; however, a significantly higher relapse rate was found in patients with AML treated with Haplo-Cord (HR, 2.3; 95% CI, 1-5.4; P = .04). Our study confirms that Haplo-Cord was an effective strategy to accelerate neutrophil and platelet recovery and shows that, in the context of specific treatment platforms, sUCBT and Haplo-Cord offer similar long-term outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sanz J, Kwon M, Bautista G, et al. Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Blood Adv. 2017. PMID: 29296747. doi:10.1182/bloodadvances.2017006999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。